Merck KGaA

Industry

  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Acadiana Ventures
  • Allergopharma Joachim Ganzer KG
  • AmpTec GmbH
  • Asceneuron
  • Biochrom AG
  • BioControl Systems
  • Chord Therapeutics
  • EMD Performance Materials
  • EMD Pharmaceuticals
  • EMD Serono
  • Erbi Biosystems
  • FloDesign Sonics
  • Grzybowski Scientific Inventions (GSI)
  • Intermolecular
  • JRH Biosciences
  • Laboratoires Richelet
  • Merck Hoei
  • Millipore
  • MilliporeSigma
  • Ormet Circuts
  • Serono
  • Sigma-Aldrich
  • SpringWorks Therapeutics
  • Versum Materials
See more in Biomedtracker

Latest on Merck KGaA

In Vivo

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals, a biotech that employs quantum physics and artificial intelligence for drug discovery, and Sorbonne University have launched a quantum AI model that could reduce drug synthesis

Scrip

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Who: Sanofi/Formation Bio What: The French drugmaker has licensed gusacitinib, an oral dual JAK/SYK inhibitor. Why: The companies have several long-standing pacts already in place “focused on ide

Scrip

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

Merck KGaA is pursuing a Phase III program for its novel toll-like receptor 7/8 inhibitor enpatoran in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), despite

In Vivo

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

In the top alliance by deal value, ABL Bio entered a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier shu